Comparison of Stem Cell Therapy Costs for Heart Diseases: Shanghai

Introduction

In recent years, stem cell technology has brought new therapeutic possibilities for patients with refractory cardiac diseases such as heart failure and myocardial infarction. The cost difference of cross-border medical treatment is a core consideration for many international patients when choosing treatment institutions. As one of the first batch of tertiary class A hospitals in China that have obtained the filing for stem cell clinical research, Shanghai East Hospital has witnessed its cardiac stem cell therapy technology enter a mature application stage, which has a very prominent cost-effectiveness advantage compared with similar projects in Europe, the United States and Japan.

I. Detailed Comparison of Treatment Costs

Overall Cost Range

The full-process cost of stem cell cardiac therapy at Shanghai East Hospital is 180,000 to 250,000 RMB (approximately 25,000 to 35,000 USD), covering all links including preoperative assessment, stem cell preparation, surgical operation, and 3-month postoperative follow-up. In comparison, the cost of similar projects is 150,000 to 220,000 USD in the United States, 80,000 to 120,000 USD in Japan, and 100,000 to 180,000 USD in Europe. The cost at Shanghai East Hospital is only about 1/6 of that in the United States and 1/3 of that in Japan.

Differences in Cost Structure

In the costs of Europe, the United States and Japan, the proportion of doctor service fees can reach 30%-40%, and the proportion of stem cell preparation patent fees accounts for more than 20%. While in the treatment cost of Shanghai East Hospital, the proportion of consumables and technical costs is 80%, service fees only account for 15%, and there is no need to pay additional patent authorization premium, with no hidden charging items.

II. Technical Qualification and Efficacy Guarantee

Many patients worry that low price corresponds to low quality. In fact, the cardiac stem cell therapy of Shanghai East Hospital has reached the international advanced level: the hospital is a "double-filing" institution for stem cell clinical research in China, and has completed more than 200 cases of cardiac stem cell transplantation. The left ventricular ejection fraction of patients increased by an average of 12%-15% at 1 year after surgery, which is consistent with the mainstream research data of Europe, the United States and Japan. At present, the autologous mesenchymal stem cell preparation technology used by the hospital has obtained Chinese patent authorization, with no risk of immune rejection, and the incidence of postoperative serious adverse reactions is lower than 0.5%, which is on a par with the data of Europe, the United States and Japan.

III. Practical Guide for International Patients to Seek Medical Treatment at the Hospital

Preparations in Advance: Submit past medical records (with English translation attached), echocardiography, coronary angiography and other examination reports through the International Medical Department of the hospital 1 month in advance. The hospital will issue the assessment result within 3 working days. After confirming that the patient meets the indications, the hospital will send an invitation letter to assist in handling the medical visa.

Treatment Cycle: The overall stay in China is 2 to 3 weeks, with 1 to 2 days for preoperative examination, 7 to 10 days for stem cell preparation. Patients can get out of bed on the same day of the transplantation surgery, and can be discharged after 3 to 5 days of postoperative observation. Subsequent follow-up can be completed remotely online.

Supporting Services: The International Department of the hospital provides full-process English medical guidance, Chinese-English bilingual comparison of cost details, and direct settlement services connected with overseas insurance. There are international apartments in the surrounding area, and the accommodation cost is only 1/4 of that of seeking medical treatment in Europe, the United States and Japan.

Conclusion

For international patients in need of stem cell cardiac therapy, Shanghai East Hospital can greatly reduce the medical cost on the premise of ensuring the therapeutic effect and safety. It is recommended that patients first confirm the stem cell clinical qualification and past case data of the institution before choosing an institution, and then make a comprehensive decision combined with their own economic situation and time cost, so as to avoid choosing low-price institutions without compliant qualifications and ensure medical safety.